Incidence of thrombocytopenia in solid tumor patients received chemotherapy at Sunpasitthiprasong Hospital; a retrospective study

Abstract

Cancer is a high incidence and mortality rate disease. Chemotherapy is a cornerstone of cancer treatment. Which has been reported not only to increase survival rate but also to develop many side effects including thrombocytopenia. This study aimed to investigate the incidence of thrombocytopenia in solid tumor patients who received chemotherapy. Methods: This study was conducted solid tumor patients received chemotherapy at Sunpasitthiprasong hospital during January 1st, 2021 – June 30th, 2021. An incidence of thrombocytopenia was analyzed by descriptive statistic. Wilcoxon Signed Ranks test was performed to analyze platelet count before and after chemotherapy treatment. To compare a length of hospital stay between patients with and without thrombocytopenia, T-Test statistics was chosen. A relationship between changing of platelet count and the number of cycles of chemotherapy and changing of other hematologic parameters were analyzed by simple linear regression. SPSS statistics program (version 29) was used for statistical analysis and data management. Results: A 415 solid tumor patients with 3,429 chemotherapy cycles were enrolled. An incidence of thrombocytopenia was 9.3% of which 89.9% had grade 1 severity. A platelet count before and after received chemotherapy was significantly decreased from 320,000 cells/mm3 to 263,000 cells/mm3 (p-value <0.05). Furthermore, this study found a relationship between an increasing of chemotherapy cycles and decreasing of platelet count and reducing of white blood cells and neutrophil. Conclusion: This study found the incidence of thrombocytopenia was 9.3%. Found a relationship between decreasing platelet count and chemotherapy cycles and changing of white blood cells and neutrophil.